Welcome and Opening Remarks

Welcome8:00am - 8:15amTed W. Love, M.D.
President & Chief Executive Officer, Global Blood Therapeutics, Inc.
NHLBI and SCD8:15am - 8:45amW. Keith Hoots, M.D.
Director of the Division of Blood Diseases and Resources at the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health


Panel 1: Beyond VOC – Clinical Consequences of SCD

Moderator8:45am - 9:45amKen Bridges, M.D.
Vice President of Medical Affairs, Global Blood Therapeutics, Inc.
PresentationAnemia and Clinical Sequelae in SCD:
Victor R. Gordeuk, M.D.
Professor of Medicine, Director, Sickle Cell Center, University of Illinois at Chicago
PresentationNeurocognitive Impact of SCD:
Carlton Dampier, M.D.
Professor of Pediatrics, Emory University School of Medicine
PresentationChronic Organ Failure in SCD:
Elliott Vichinsky, M.D.
Medical Director, Hematology/Oncology, UCSF Benioff Children's Hospital Oakland


Break (9:45am – 10:00am)


Panel 2: Impact of SCD on Quality of Life

Moderator10:00am - 10:45amLanetta Bronte, M.D., M.P.H., MSPH
President & Chief Executive Officer, Foundation for Sickle Cell Disease Research, Sickle Cell Care and Research Network
PanelistsDr. Lakiea Bailey, Ph.D.
Founder, Sickle Cell Community Consortium

Charlotte Flemmings, B.A., M.P.A.
Founder, Sickle Cycle

Dominique Goodson, B.A.
Lead Advisor, Young Adult Sickle Cell Alliance

Dr. Terry Jackson, Ph.D.
Owner, Jaxsun Enterprises

Dr. Carolyn Rowley, Ph.D.
Executive Director, Cayenne Wellness Center and Children’s Foundation

Cassandra Trimnell, B.A.
Founder & Executive Director, Sickle Cell 101


Panel 3: Innovative Care Delivery – HRSA SCD Treatment Demonstration Project

Moderator10:45am - 11:45amEdward Donnell Ivy, M.D., M.P.H.
Medical Officer, Genetic Services Branch, Division of Services for Children with Special Health Needs, Maternal and Child Health Bureau, Health Resources and Services Administration
PresentationDiane Nugent, M.D.
Clinical Professor and Chief of Hematology, Dept. of Pediatrics, UC Irvine School of Medicine, Founder, Medical Director, Center for Inherited Blood Disorders

Lisa M. Shook, M.A., MCHES, CCP
Assistant Professor of Pediatrics, Cincinnati Children’s Hospital Medical Center

Rosalyn Stewart, M.D., MBA, MS
Associate Professor,
Departments of Internal Medicine and Pediatrics, School of Nursing and Bloomberg School of Public Health Associate Professor of Medicine, Johns Hopkins University

John J. Strouse, M.D., Ph.D.
Associate Professor of Medicine and Pediatrics and Director of the Adult Sickle Cell Program, Duke University


Panel 4: SCDAA Update

Presentation11:45am - 12:15pmBeverley Francis-Gibson, B.A., M.A.
President & Chief Executive Officer, Sickle Cell Disease Association of America, Inc.


Lunch (12:15pm – 1:00pm)


Panel 5: What is Fueling the Increased Biopharma Attention on SCD? – Research Analyst Panel

Moderator1:05pm - 1:35pmMyesha Lacy
Vice President of Investor Relations and Corporate Communications, Global Blood Therapeutics, Inc.
PanelistsMark Breidenbach, Ph.D.
Executive Director and Senior Analyst Emerging Biotechnology, Oppenheimer & Co.

Raju Prasad, Ph.D.
Analyst, William Blair


Company Presentations

Global Blood Therapeutics, Inc.1:35pm - 2:00pmTed W. Love, M.D.
President & Chief Executive Officer
ADDMEDICA2:00pm - 2:25pmBernard Dauvergne, PharmD
Executive Director
CRISPR Therapeutics, Inc.2:25pm - 2:50pmKrista McKerracher
Vice President and Head, Hemoglobinopathy Programs
Emmaus Life Sciences, Inc.2:50pm - 3:15pmDarrell W. Harrington, M.D., MACP
Chief Medical Officer
Break (3:15pm - 3:30pm)
Imara, Inc.3:30pm - 3:55pmRahul Ballal, Ph.D.
Chief Executive Officer
Ironwood Pharmaceuticals, Inc.3:55pm - 4:20pmMark Currie, Ph.D.
Senior Vice President, Chief Scientific Officer, and President of R&D
Modus Therapeutics AB4:20pm - 4:45pmEllen Donnelly, Ph.D.
Chief Executive Officer



Closing4:45pm - 4:50pmTed W. Love, M.D.
President & Chief Executive Officer, Global Blood Therapeutics, Inc.


Reception (5:00pm – 6:30pm)